Formycon AG (FSE: FYB, Prime Standard) and OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) announced a strategic manufacturing partnership for biosimilars on July 14, 2026. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon, providing integrated Drug Substance and Drug Product manufacturing from its biologics facility in Bangalore, India. The collaboration combines Formycon’s biosimilar development expertise with OneSource’s end-to-end biologics manufacturing capabilities to support Formycon’s biosimilar programs for global markets.
Dr. Stefan Glombitza, CEO of Formycon AG, stated: “Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency. Together, we aim to broaden sustainable global access to life-changing biosimilar therapies.”
Neeraj Sharma, Managing Director & CEO of OneSource Specialty Pharma, commented: “We are delighted to partner with Formycon, one of the world’s leading biosimilar developers with a proven track record of bringing high-quality biosimilars to global markets. This partnership brings together Formycon’s development expertise and OneSource’s integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide. It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacturing of world-class biologics.”
The partnership reflects both companies' commitment to advancing global access to biosimilars through reliable, high-quality, and scalable manufacturing. Achieving this requires a sustainable, cost-effective manufacturing model, which OneSource is positioned to deliver. Formycon brings a strong track record in biosimilar development and commercialization, supported by an established portfolio and a robust pipeline. OneSource complements this with an integrated biologics platform spanning cell line development through commercial fill-finish, five manufacturing facilities approved by leading global regulatory authorities including the US FDA and EMA, and extensive expertise across biologics, sterile injectables, and drug-device combinations.
Formycon, headquartered in Munich and listed in the Prime Standard of the Frankfurt Stock Exchange, is a leading independent developer of high-quality biosimilars. The company covers the entire value chain from candidate selection to market-ready product delivery. With FYB201/ranibizumab, FYB202/ustekinumab, and FYB203/aflibercept already on the market, and four pipeline candidates including FYB206/pembrolizumab and FYB208/dupilumab in development, Formycon is making an important contribution to providing patients with access to highly effective and affordable medicines. More information can be found at https://www.formycon.com/.
The FYB4Growth strategy is based on four pillars: geographic diversification into high-growth regions like MENA, APAC, and Latin America; a smart portfolio strategy combining blockbuster molecules with niche products; excellence and innovation in technology and regulatory development; and consistent cost efficiency through streamlined processes and digital technologies. Find out more at https://www.fyb4growth.com.
OneSource Specialty Pharma is a pure-play global CDMO focusing on complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies. With five state-of-the-art manufacturing facilities approved by global regulatory authorities and a team of over 1,600 professionals, OneSource provides efficient, end-to-end solutions. For more information, visit www.onesourcecdmo.com.
This partnership underscores the importance of cost-efficient manufacturing in expanding access to biosimilars, which are successor products to biopharmaceutical drugs whose patents have expired. With global biosimilar sales currently around $21 billion and projected to exceed $74 billion by 2030, such collaborations are crucial for reducing healthcare costs and increasing patient access to biologic therapies.
